Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...

Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

Neurocrine stock crashed to a three-month low Friday after the company's bread-and-butter drug and its guidance for 2025 both lagged Wall Street's expectations.The company is best known for its drug, ...

Fate’s Market in Remus Michigan partners with Great Start Collaborative of Mecosta, Osceola counties to make shopping into a learning experience for children.

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...